NCT07188740View on ClinicalTrials.gov

Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2029

Conditions

DNMT3A Gene Mutation

Interventions

DRUG

Metformin

Start at 500 mg twice daily, titrate to 2000 mg/day for 6 months

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER